MBIO
Price
$1.02
Change
-$0.01 (-0.97%)
Updated
Jun 27 closing price
Capitalization
4.47M
MIRM
Price
$51.09
Change
+$0.53 (+1.05%)
Updated
Jun 27 closing price
Capitalization
2.53B
32 days until earnings call
Interact to see
Advertisement

MBIO vs MIRM

Header iconMBIO vs MIRM Comparison
Open Charts MBIO vs MIRMBanner chart's image
Mustang Bio
Price$1.02
Change-$0.01 (-0.97%)
Volume$172.48K
Capitalization4.47M
Mirum Pharmaceuticals
Price$51.09
Change+$0.53 (+1.05%)
Volume$939.54K
Capitalization2.53B
MBIO vs MIRM Comparison Chart in %
Loading...
MBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MIRM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MBIO vs. MIRM commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBIO is a Buy and MIRM is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (MBIO: $1.02 vs. MIRM: $51.09)
Brand notoriety: MBIO and MIRM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MBIO: 32% vs. MIRM: 226%
Market capitalization -- MBIO: $4.47M vs. MIRM: $2.53B
MBIO [@Biotechnology] is valued at $4.47M. MIRM’s [@Biotechnology] market capitalization is $2.53B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MBIO’s FA Score shows that 0 FA rating(s) are green whileMIRM’s FA Score has 1 green FA rating(s).

  • MBIO’s FA Score: 0 green, 5 red.
  • MIRM’s FA Score: 1 green, 4 red.
According to our system of comparison, MIRM is a better buy in the long-term than MBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MBIO’s TA Score shows that 3 TA indicator(s) are bullish while MIRM’s TA Score has 5 bullish TA indicator(s).

  • MBIO’s TA Score: 3 bullish, 6 bearish.
  • MIRM’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, MIRM is a better buy in the short-term than MBIO.

Price Growth

MBIO (@Biotechnology) experienced а -2.86% price change this week, while MIRM (@Biotechnology) price change was +1.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

MIRM is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MIRM($2.53B) has a higher market cap than MBIO($4.47M). MIRM YTD gains are higher at: 23.555 vs. MBIO (-88.475). MBIO has higher annual earnings (EBITDA): -10.6M vs. MIRM (-37.56M). MIRM has more cash in the bank: 278M vs. MBIO (14.2M). MBIO has less debt than MIRM: MBIO (0) vs MIRM (317M). MIRM has higher revenues than MBIO: MIRM (379M) vs MBIO (0).
MBIOMIRMMBIO / MIRM
Capitalization4.47M2.53B0%
EBITDA-10.6M-37.56M28%
Gain YTD-88.47523.555-376%
P/E RatioN/AN/A-
Revenue0379M-
Total Cash14.2M278M5%
Total Debt0317M-
FUNDAMENTALS RATINGS
MBIO vs MIRM: Fundamental Ratings
MBIO
MIRM
OUTLOOK RATING
1..100
5241
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
10014
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
9541
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MIRM's Valuation (66) in the null industry is in the same range as MBIO (91) in the Pharmaceuticals Major industry. This means that MIRM’s stock grew similarly to MBIO’s over the last 12 months.

MIRM's Profit vs Risk Rating (14) in the null industry is significantly better than the same rating for MBIO (100) in the Pharmaceuticals Major industry. This means that MIRM’s stock grew significantly faster than MBIO’s over the last 12 months.

MIRM's SMR Rating (96) in the null industry is in the same range as MBIO (100) in the Pharmaceuticals Major industry. This means that MIRM’s stock grew similarly to MBIO’s over the last 12 months.

MIRM's Price Growth Rating (41) in the null industry is somewhat better than the same rating for MBIO (95) in the Pharmaceuticals Major industry. This means that MIRM’s stock grew somewhat faster than MBIO’s over the last 12 months.

MIRM's P/E Growth Rating (100) in the null industry is in the same range as MBIO (100) in the Pharmaceuticals Major industry. This means that MIRM’s stock grew similarly to MBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MBIOMIRM
RSI
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
76%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
75%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
87%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
MBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MIRM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AUUD6.001.49
+33.04%
Auddia Inc
TXRH187.742.71
+1.46%
Texas Roadhouse
RSI14.710.20
+1.38%
Rush Street Interactive
PJT166.410.05
+0.03%
PJT Partners
RILY2.93-0.06
-2.01%
B. Riley Financial

MBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MBIO has been loosely correlated with SLRX. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if MBIO jumps, then SLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBIO
1D Price
Change %
MBIO100%
-0.97%
SLRX - MBIO
63%
Loosely correlated
-0.01%
IPHYF - MBIO
42%
Loosely correlated
N/A
SCNI - MBIO
37%
Loosely correlated
-7.69%
MIRM - MBIO
34%
Loosely correlated
+1.05%
GLSI - MBIO
32%
Poorly correlated
N/A
More

MIRM and

Correlation & Price change

A.I.dvisor indicates that over the last year, MIRM has been loosely correlated with NRIX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MIRM jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MIRM
1D Price
Change %
MIRM100%
+1.05%
NRIX - MIRM
47%
Loosely correlated
+0.17%
CRNX - MIRM
46%
Loosely correlated
-0.10%
RVMD - MIRM
43%
Loosely correlated
-1.52%
IRON - MIRM
42%
Loosely correlated
+0.68%
KYMR - MIRM
41%
Loosely correlated
-3.48%
More